Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) Director John Kiely sold 50,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director owned 210,252 shares of the company’s stock, valued at $3,708,845.28. This trade represents a 19.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Amneal Pharmaceuticals Trading Up 5.1%
AMRX opened at $18.15 on Friday. The stock has a market capitalization of $5.80 billion, a PE ratio of 37.04 and a beta of 1.27. Amneal Pharmaceuticals, Inc. has a one year low of $9.20 and a one year high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The business’s 50 day moving average price is $17.24 and its 200 day moving average price is $14.59.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on AMRX. UBS Group raised their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $17.67.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of AMRX. Rubric Capital Management LP boosted its holdings in Amneal Pharmaceuticals by 5.3% during the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after buying an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Amneal Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after buying an additional 81,546 shares in the last quarter. Morgan Stanley lifted its position in shares of Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after acquiring an additional 1,315,018 shares during the period. Nantahala Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 14.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after acquiring an additional 558,877 shares during the period. Finally, State Street Corp boosted its stake in shares of Amneal Pharmaceuticals by 3.4% during the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after acquiring an additional 136,662 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Read More
- Five stocks we like better than Amneal Pharmaceuticals
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
